Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial

BACKGROUND: Wear-induced osteolysis is the main factor in reducing the longevity of total hip arthroplasty (THA). The transmembrane Receptor Activator of Nuclear Factor κ B (RANK) and its corresponding ligand RANKL is an important regulator of osteoclast activity and bone resorption and is associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Sköldenberg, Olof, Rysinska, Agata, Eisler, Thomas, Salemyr, Mats, Bodén, Henrik, Muren, Olle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841945/
https://www.ncbi.nlm.nih.gov/pubmed/27108405
http://dx.doi.org/10.1186/s12891-016-1036-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841945/
https://www.ncbi.nlm.nih.gov/pubmed/27108405
http://dx.doi.org/10.1186/s12891-016-1036-5

Ejemplares similares